Безопасность и риск фармакотерапии (Feb 2018)
Ketoacidosis as unexpected adverse reaction SGLT<sub>2</sub> inhibitor
Abstract
Inhibitors of the sodium-glucose cotransporter-2 SGLT2 is a new class of hypoglycemic drugs. This article presents the information on FDA reports (2013-2015) and AIS (May 2015 - February 2016) on the risk of new adverse reaction - ketoacidosis. Conjectural pathophysiological mechanisms of ADR associated with this class of drugs, which could lead to its development are presented.